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Abstract
Objectives Death domain-associated protein (Daxx) has been
recently implicated as a positive factor in ovarian cancer and
prostate cancer, but the role of Daxx in oral squamous cell
carcinoma (OSCC) has never been addressed. Herein, we in-
vestigate the expression and function of Daxx in OSCC.
Materials and methods RT-quantitative PCR, Western blot-
ting, and immunohistochemistry were used to evaluation of
the expression of Daxx in human OSCC cell lines and clinical
surgical specimens. Short hairpin RNA targeting Daxx was
transduced by lentivirus infection to knockdown the expres-
sion of Daxx in SAS and SCC25 cell lines, and the influence
of this knockdown was evaluated by analyzing the growth and
the cell cycle in transduced cells. Immunoprecipitation
and sequent ial chromatin immunoprecipi tat ion-
quantitative PCR were used to analyze the associations
between Daxx, TCF4, and cyclin D1 promoter.
Xenograft tumor model was used to evaluate the
in vivo tumorigenicity of Daxx in OSCC.
Results Daxx mRNA and protein expression are elevated in
several OSCC cell lines and human OSCC samples in com-
parison to those in normal tissue. We further find that deple-
tion of Daxx decreases OSCC cell growth activity through G1
cell cycle arrest. Daxx silencing reduces cyclin D1 expression
via a Daxx-TCF4 interaction, whereas the Daxx depletion-
mediated G1 arrest can be relieved by ectopic expression of
cyclin D1. Moreover, we show that in OSCC clinical samples,
the expression of Daxx is significantly correlated with that of
cyclin D1.
Conclusion Our data demonstrate the importance of Daxx in
regulation of cyclin D1 expression and provide the first evi-
dence that Daxx exhibits tumor-promoting activity in OSCC.
Clinical relevance Daxx plays an important role in malignant
transformation of OSCC and may serves as a target for cancer
prevention and treatment.
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Introduction
Head and neck squamous cell carcinomas, including oral
squamous cell carcinomas (OSCC), are the eighth most prev-
alent new cancer cases among men in the USA in 2014 [1].
The clinical outcome and prognosis for OSCC are dismal;
more than 61 % of patients die of this disease or its complica-
tions within 5 years [2]. Thus, identifying cancer relative mo-
lecular markers for clinical histopathologic exams and finding
the regulatory mechanisms of tumorigenicity in OSCC are
necessary for development of potential therapeutics.
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Daxx is a predominant nuclear protein that associates with
several different subnuclear structures, including the PML nu-
clear body, heterochromatin, and nucleolus [3]. There are nu-
merous reported functions for Daxx, acting as apoptosis reg-
ulator and transcription co-regulator in a SUMO binding-
dependent or binding-independent manner [3–5]. Moreover,
cooperation of Daxx with the chromatin remodeler ATRX is
r equ i r ed fo r h i s t one H3 .3 depos i t i on a t t h e
pericentromeric and telomere regions; H3.3 deposition
facilitates transcript expression from pericentromeric re-
gions [6]. Analysis derived from clinical samples in
pancreatic neuroendocrine tumors (PanNETs) revealed a
high ratio of inactivating-to-missense mutations in the
coding region of Daxx [7]. Daxx has been recently im-
plicated as a tumor promoting factor in ovarian cancer
and prostate cancer, but the role of Daxx in OSCC has
never been addressed [8, 9].
Although several Daxx-interacting proteins are involved in
critical cellular pathways regarding P53 degradation, such as
ubiquitin-specific-processing protease 7 (USP7) and mouse
double minute 2 (Mdm2) [10, 11], it is still unclear whether
Daxx has any role in tumorigenicity of OSCC. In the present
study, we investigated the expression and the function of Daxx
in OSCC. Our results provide the first evidence of elevated
Daxx expression in both OSCC cell lines and clinical samples.
We further demonstrated that Daxx silencing by RNAi re-
duces the cell growth of OSCC in vitro and in vivo. Daxx
silencing reduces cyclin D1 expression and increases the frac-
tion of cells in the G1 phase in OSCC, whereas ectopic ex-
pression of cyclin D1 eliminates the Daxx depletion-induced
G1 cell cycle arrest. Together, our results suggest that Daxx
silencing reduces OSCC cell growth through cyclin D1
downregulation.
Materials and methods
Tissue samples and ethics statement
All OSCC and matched normal tissues were obtained from 18
OSCC patients in the Department of Oral and Maxillofacial
Surgery at Tri-Service General Hospital, Taiwan. The clinical
and histological characteristics of the surgical specimens were
presented in an additional Table 1. The experiments
were under-taken following the approval by the Ethical
Committee of Tri-Service General Hospital IRB protocol
096-05-002-I and 02-101-05-082, and written informed
consents were obtained from all patients. The animal
experiments were under-taken following the approval
by the Institutional Animal Care and Use Committee
of National Defense Medical Center IACUC protocol
11-084. All efforts were made to minimize the suffering
of experimental animals.
Cells, siRNA, plasmids, and transfection
293T, WI38, and SCC25 cell lines were obtained from the
American Type Culture Collection. The 293Tand SCC25 cell
lines used have been previously described in detail [5, 12].
Cell line WI38 was maintained in a minimal amount of essen-
tial medium supplemented with 10 % fetal bovine serum
(FBS, non-essential amino acids, 1 mM sodium pyruvate,
2 mM L-glutamine, and antibiotics). The SAS cell line was
provided by Dr. Jeng-Fan Lo and was grown in high glucose
DMEM with 10 % FBS, as described [13]. The specific
siRNA oligonucleotides used against Daxx and for negative
controls were synthesized by Life Technologies [14]. The len-
tivirus plasmid expressing shLuc and shDaxx were obtained
from the RNAi consortium at Academia Sinica. The shDaxx
nucleotide sequences corresponded to Daxx coding sequence
1585-1605. Cyclin D1 plasmid was donated by Dr. William
Hahn (Addgene plasmid no. 9050). Plasmids were isolated
using a GenElute HP EndoFree Plasmid Maxiprep Kit
(Sigma, St. Louis, MO, USA), and transfection was
Table 1 Clinical and histological characteristics of the 25 cases of
p r imary human ora l squamous ce l l c a r c inoma used in
immunohistochemical analysis
Case No. Gender Age Anatomic site Stage Histological grade
1 Male 63 Anterior pillar I Moderate
2 Male 37 Buccal IVa Poor
3 Male 44 Buccal III Poor
4 Male 66 Buccal III Moderate
5 Male 47 Buccal IVa Moderate
6 Male 44 Buccal IVa Moderate
7 Male 52 Buccal IVa Poor
8 Male 60 Gingiva IVa Moderate
9 Female 42 Gingiva I Moderate
10 Male 82 Gingiva I Moderate
11 Female 75 Gingiva IVa Well
12 Male 71 Lip II Moderate
13 Male 52 Mandible IVb Moderate
14 Male 57 Mouth floor IVa Poor
15 Male 39 Mucosa IVa Moderate
16 Male 48 Oral cavity III Poor
17 Male 45 Soft palate III Moderate
18 Male 40 Tongue I Well
19 Male 47 Tongue IVa Moderate
20 Male 44 Tongue IVa Poor
21 Male 52 Tongue I Moderate
22 Male 70 Tongue I Moderate
23 Female 74 Tongue III Moderate
24 Male 47 Tongue II Moderate
25 Female 48 Tongue II Poor
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performed with a PolyJet (SignaGen Laboratories Ijamsville,
MD, USA), according to the manufacturer’s instructions.
Immunoprecipitation and Western blotting assays
Cells were lysed directly in an RIPA buffer containing 50 mM
Tris (pH 7.8), 0.15 M NaCl, 5 mM EDTA, 0.5 % Triton
X-100, 0.5 % NP-40, 0.1 % sodium deoxycholate, and prote-
ase inhibitor mixture (Sigma). The relative protein concentra-
tion in the supernatants was determined using a BCA protein
assay kit (Thermo Scientific, Rockford, USA). For immuno-
precipitation, 400 μg of protein lysates were incubated with
specific antibodies. For each lane of 8 to 10 % SDS–PAGE
gel, 40 μg protein of cell lysates were loaded, separated, and
transferred onto polyvinyldifluoride (PVDF) membrane
(Millipore, Bedford, MA, USA). The membranes were then
probed using specific antibodies against Daxx (Sigma,
D7810), cyclin D1 (Santa Cruz Biotech, Santa Cruz, CA,
USA, sc-718), and β-actin (Sigma, A5441).
RT-quantitative PCR
Total RNAwas extracted from these cells using TRIzol (Life
Technologies, Carlsbad, CA, USA) or Total RNA Miniprep
Purification kit (GeneMark, Taipei, Taiwan). Five micrograms
of RNA from each sample were then reverse transcribed using
Superscript III Reverse Transcriptase (Life Technologies). RT-
quantitative PCR (RT-qPCR) was performed using SYBR
Green PCR master mix (Life Technologies) and an ABI
7500 sequence detection system (Life Technologies). The
RT-qPCR primers used were as follows: Daxx forward, 5′-
TGC AGA CAC CCC CGA AGC CT-3′; Daxx reverse prim-
er, 5′-TGC CAT TCC ACT AGG GCC CTC A-3′; GAPDH
forward, 5′-TCT TTT GCG TCG CCA GCC GAG-3′;
GAPDH reverse primer, 5′-TGA CCA GGC GCC CAA
TAC GAC-3′; cyclin D1 forward primer, 5′-TGT GAC CCG
GACTGCCTCCG-3′; and cyclin D1 reverse primer, 5′-GCG
CAG GCT TGA CTC CAG CA-3′.
Cell cycle analysis
Infected cells and transfected cells were harvested for the in-
dicated periods, washed with ice-cold PBS, fixed overnight
with 70% ethanol at 4 °C, and then suspended in 500μL PBS.
After adding 10 μL RNase A (Sigma, 10 mg/mL), cells were
allowed to stand at 37 °C for 30 min, stained with 10 μL 7-
AAD (Sigma, 1 mg/mL), and then analyzed by flow cytome-
try. Flow cytometric analysis was performed using
FACSCaliber (BD Biosciences, San Jose, CA, USA), and
the data were analyzed using CellQuest software (BD
Biosciences).
Lentivirus production and infection
The replication deficient lentivirus was prepared by
transfecting 293T cells with plasmids using a PolyJet
(SignaGen Laboratories). Viral supernatants were harvested
72 h after transfection, clarified through centrifugation, fil-
tered, and stored in aliquots at −80 °C. Cells were infected
by lentivirus supernatants in the presence of 7.5 μg/mL
Polybrene (Sigma) for 24 h.
Xenograft tumor model
Eight-week-old NOD.CB17 Prkdcscid/J (National Laboratory
Animal Center, Taiwan) mice were maintained in
microisolator in pathogen free conditions. Five mice per
group, which were randomly assigned, were injected subcu-
taneously with either shLuc or shDaxx lentivirus infected SAS
cells. The sizes of the transplanted tumors were measured with
gauged calipers every 3 days, and the tumor volumes were
calculated using the following formula: V=1/2×(length×
width2). At the end of treatment, the mice were euthanized,
and the tumors were removed, weighed, and photographed.
Immunohistochemistry
Parraffin sections were deparaffinized with xylene and
rehydrated with a serial grade of alcohol. Epitope retrieval
was carried out in a 10-mM citrate buffer (pH 6.0) water
bathed at 90 °C on a hot plate for 18 min. After inactivation
of endogenous peroxidase with H2O2, these slides were then
incubated with specific antibodies against Daxx (Sigma,
D7810) or cyclin D1 (Sigma, HPA027801) for 1 h at room
temperature. Immunostaining was performed according to
standard procedures. Envision plus kit (DAKO, Carpinteria,
CA, USA) was used as a secondary reagent. Stainings were
developed using DAB (brown precipitate). Slides were coun-
terstained with hematoxylin and visualized by light microsco-
py. All immunostains were evaluated by two pathologists.
Staining percentage was scored by counting the numbers of
staining positive and calculating the percentage of positive
cells. The scores of staining percentage was defined as 0
(0 %), 1 (1–25 %), 2 (26–50 %), 3 (51–75 %), and 4 (76–
100 %). Staining intensity was determined by estimating the
signal density and scored as 0 (no detectable stain), 1 (weak
staining detected at intermediate to high power), 2 (moderate
detected at low to intermediate power), to 3 (strong detected at
low power). The final immunoreactivity score was scored by
multiplying the staining percentage of positive cells by the
staining intensity. Sample scores of 7–12 were defined as hav-
ing high immunoreactivity, and sample scores of 0–6 were
defined as having low immunoreactivity.
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Sequential chromatin immunoprecipitation-quantitative
PCR assay
Chromatin immunoprecipitation-quantitative PCR (ChIP-
qPCR) was performed as previously described [5]. ChIP-
qPCR product was analyzed by quantitative real-time PCR
using the Applied Biosystem 7500 Real-Time PCR System.
A fraction (1 %) of the sonicated chromatin was set aside as
input control before antibody affinity manipulations. Percent
input was calculated by 100  2 Ctadjusted Input−CtIPð Þ. Primers
used to amplify DNA fragments containing the TCF4 consen-
sus site were 5′-AGG CGC GGC GGC TCA GGG ATG-3′
and 5′-ACTCTGCTGCTCGCTGCTACT-3′ for the human
cyclin D1 promoter [15].
Statistical analysis
All analyses performed with SigmaPlot software. The two-
tailed Students’s t test was used to evaluate the significance
of the differences between two groups of data in all experi-
ments. Values of P<0.05 were considered significant.
Results
Daxx expression is frequently upregulated in both OSCC
human samples and cell lines
To examine whether Daxx expression were dysregulated in
human OSCC samples, we measured the Daxx mRNA levels
in 18 pairs of OSCC tissues and their matched normal mucosa
tissues. Among the 18 patients, 14 (78 %) patients showed
higher Daxx RNA level in the OSCC tissues than that in ad-
jacent normal mucosa tissues (Fig. 1a). We further analyzed
Daxx protein in a set of human OSCC samples and observed
that Daxx expression was significantly higher in OSCC tis-
sues than in normal mucosa tissues (Fig. 1b). Notably, Daxx
was located in nuclei of normal mucosa tissue and OSCC
tissue (Fig. 1c). The results indicated that higher staining in-
tensity and percentage of Daxx positive cells in tumor tissue
compared to normal tissue (Fig. 1c). We also investigated the
expression levels of Daxx in OSCC cell lines (SCC25 and
SAS) and a normal cell line (WI38). SCC25 and SAS cell
lines expressed higher levels of Daxx than WI38 cell line
(Fig. 1d). Taken together, Daxx expression is frequently up-
regulated in both OSCC clinical samples and OSCC cell lines.
Downregulation of Daxx reduces the growth of OSCC
cells in vitro and in vivo
The elevated Daxx expression in both OSCC cell lines
and OSCC clinical samples led us to investigate
whether endogenous Daxx affects the growth capability
of OSCC cell. Lentivirus-mediated shRNA was used to
knockdown the Daxx protein expression in both SCC25
and SAS OSCC cell lines. This shDaxx plasmid has
been widely used to target Daxx mRNA in several
studies [5, 16]. The results indicated that effective si-
lencing of Daxx expression in SCC25 and SAS cells
significantly reduces the cell number compared to con-
trol cells at day 3 after infection (Fig. 2a, b). Another
siRNA oligo against Daxx in a different coding region
was also used. Consistent with the lentivirus results,
Daxx siRNA (siDaxx) decreases SAS cell viability
compared to control cells at day 3 after transfection
(Fig. 2c). Xenograft tumor experiments were used to
extend the study of endogenous Daxx in tumorigenici-
ty. The results indicated that shDaxx-infected cells sig-
nificantly reduce tumor growth rates in NOD/SCID
mice compared with shLuc-infected cells (Fig. 2d).
Collectively, these results further support the notion
that suppression of Daxx expression significantly de-
creases the tumor growth of OSCC.
Daxx silencing reduces cyclin D1 expression via
a Daxx-TCF4 interaction
It has been previously reported that Daxx regulates the expres-
sion of cyclin D1 at the transcription level in colorectal cancer
[17] and that cyclin D1 is important for OSCC growth activity
[18]; we therefore tested whether Daxx can regulate cyclin D1
expression in OSCC using OSCC cell line. We found that
suppression of Daxx by RNAi decreases the mRNA transcrip-
tion and protein expression of cyclin D1 in SAS cells, an
OSCC cell line (Fig. 3a). Previous studies indicated that ex-
pression of cyclin D1 is strongly dependent on β-catenin/
TCF4-mediated transcriptional regulation [19]. We showed
an endogenous interaction between Daxx and TCF4 in SAS
cells using immunoprecipitation (IP) followed by
Western blotting (Fig. 3b, left panel). Moreover, the
association of Daxx and TCF4 was found on endoge-
nous cyclin D1 promoter in SAS cells as evidenced by
the presence of the TCF4-containing DNA fragment
precipitated by anti-TCF4 antibody followed by sequen-
tial chromatin immunoprecipitation (ChIP) with anti-
Daxx antibody but not by a control antibody (Fig. 3b,
right panel). As we hypothesized that transcription of
cyclin D1 is regulated by Daxx, we therefore examined
whether cyclin D1 is coexpressed with Daxx in human
OSCC samples. We evaluated Daxx and cyclin D1 ex-
pression in OSCC clinical samples by RT-qPCR and
found a strong correlation between Daxx and cyclin
D1 expression (r=0.7074, P=0.0149, data not shown).
Similar results were also observed from immunohisto-
chemistry (Fig. 3c, n=25). Accordingly, Daxx expression
536 Clin Oral Invest (2016) 20:533–540
level was correlated with cyclin D1 level in different OSCC
samples (Fig. 3d). Together, our results suggest that Daxx
functions as a positive regulator in modulating cyclin D1 ex-
pression via interacting with TCF4 in OSCC cells.
Fig. 1 Daxx expression is
frequently upregulated in OSCC
clinical samples and OSCC cell
lines. a Quantitative RT-PCR
results from 18 pairs of matched
normal mucosa tissue and OSCC
tissues. b Immunohistochemitry
of Daxx expression in a normal
mucosa tissue and OSCC tissue.
Statistical significance was
ascertained by conducting
Student’s t tests. c Positive
nuclear immunolabeling of Daxx
in normal mucosa tissue and
OSCC tissue. Scale bar=200 um.
dWestern blots of Daxx
expression in a normal cell line
(WI38) and two human OSCC
cell lines (SCC25 and SAS). β-
actin was used as a loading
control
Fig. 2 RNAi-mediated down-regulation of Daxx reduces the growth
activity of OSCC cells in vitro and in vivo. a SCC25 and b SAS cells
infected with shLuc and shDaxx lentivirus were counted at the indicated
times. Infected cells were then subjected to Western blots with indicated
antibodies. c SAS cells transfected with siControl and siDaxx were count-
ed at day 3 after transfection and subjected toWestern blots with indicated
antibodies. d SAS cells infected with shLuc and shDaxx were
subcutaneously xenografted into NOD/SCIDmice (n=5 mice per group).
Data are represented as mean±SEM. The tumor size was analyzed using
Student’s t test at day 42 after tumor cell injection (left panel). Top right
panel: Western blot of an aliquot of the infected cells before injection.
Bottom right panel: tumors from SAS/shLuc or SAS/shDaxx were
excised at day 42
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Daxx silencing induces cyclin D1-mediated G1 arrest
in OSCC cells
Given that cyclin D1 plays a critical role in the G1 to S phase
cell cycle transition [19], we expect that Daxx silencing
should induce G1 arrest. We therefore examined the effects
of Daxx silencing on cell-cycle progression. Indeed, suppress-
ing Daxx in SCC25 and SAS cells enhanced the portion of
cells in the G1 phase (Figs. 4a, b). To confirm this notion,
cyclin D1 was ectopically expressed in Daxx-depleted SAS
cells. Our results showed that ectopic expression of cyclin D1
eliminates Daxx depletion-induced G1 arrest (Fig. 4c). Taken
together, Daxx regulates the growth activity of OSCC cells
which may be associated with cyclin D1.
Discussion
Aberration of cell cycle regulation accounts for many abnor-
mal biological behavior of cancer cells. In this study, we show
that Daxx silencing in OSCC cells increases the number of
G1-arrested cells through downregulating cyclin D1 expres-
sion. Cyclin D1 is a vital protein that controls the transition
from G1 to S phase and governs the rate of cell proliferation.
Increase or upregulation of cyclin D1 has been reported in
about 36 to 56 % of OSCC patients, and therefore, it acts as
an important genetic event in OSCC [18]. Recently, Zhao
et al. [20] indicated that cyclin D1 expression correlates with
detrimental clinicopathological outcome and poor prognosis
in OSCC. Thus, it is possible that Daxx may be used as a
prognostic factor for OSCC. In the current study, we provide
evidence for a possible link between Daxx expression level
and the pathogenesis of OSCC. How the correlation between
Daxx and cyclin D1 is involved in clinicopathological features
and poor prognosis of OSCC needs to be dissected in
the future.
In this current study, we have shown that Daxx silencing
reduces tumor growth by suppressing cyclin D1 expression in
OSCC. In line with this notion, a few recent studies indicate
that Daxx may play a tumor promoting role in several cancer
types. For example, Daxx destabilizes P53 via inhibition of
Mdm2 ubiquitination in osteosarcoma and colorectal cancer
cells [10]. In addition, Daxx potentiates TCF4/β-catenin-me-
diated transcriptional activation in colorectal cancer cells [17].
Furthermore, Daxx is frequently overexpressed in prostate
cancer cells and the expression level is significantly correlated
Fig. 3 Daxx silencing reduces cyclin D1 expression via a Daxx-TCF4
interaction. aRT-qPCR andWestern blot of cyclin D1 expression in Daxx
shRNA-infected SAS cells. Data are presented as the mean±SD from
three experiments. Statistical significance was ascertained using
Student’s t test. b Western blot and sequential chromatin
immunoprecipitation (ChIP) assays were performed with antibodies
against Daxx, TCF4, or IgG control. Input represents 5 % of the lysates
used for Western blot and 1 % of the chromatin used for ChIP,
respectively. Data are presented as the mean±SD from three
independent experiments. N.D. not detected. c A positive correlation
between Daxx (x axis) and cyclin D1 (y axis) in OSCC samples using
immunohistochemistry. Each dot corresponds to one sample. Statistical
significance was ascertained using Regression analysis. d Representative
photographs of Daxx- and cyclin D1-stained tumors collected from
OSCC clinical samples with low and high staining
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with prostate cancer stage [8, 21]. Moreover, Daxx silencing
suppresses the growth activity of human ovarian cancer cells
and mouse ovarian surface epithelial cells [9, 22].
Development of OSCC is a multi-step progressing process
of transformation from healthy mucosa to invasive carcinoma.
Each step is accompanied by specific genetic alterations, in-
cluding inactivation of P53 and overexpression of cyclin D1
[23]. Since Daxx is a negative regulator of P53 and a positive
regulator of cyclin D1, these facts support the notion that
Daxx exerts a tumor promoting effect in OSCC or other types
of cancer. However, these results are derived from cell models.
It is important to explore the oncogenic contribution of
Daxx in different cancer models using conditional gene
knockout mice.
This is the first study to demonstrate the underlying mech-
anism in OSCC of how the expression of cyclin D1 is regulat-
ed by Daxx through an interaction with TCF4 on the cyclin D1
promoter. Even though the molecular basis of how Daxx en-
hances cyclin D1 expression is currently unclear, we speculate
two possible scenarios. First, Daxx may recruit CBP to poten-
tiate TCF4-mediated transactivation since Daxx could function
as a coactivator through recruiting CBP in a cell-context-
dependent manner [24]. Secondly, Daxx acts as a chaperone
for the histone variant H3.3 which is enriched at centromeric
heterochromatin, telomeres, and active genes. Therefore, Daxx
may regulate transcription through loading H3.3 at regulatory
regions [25]. These two possibilities are not mutually exclu-
sive. Further studies are required to clarify the molecularmech-
anism of Daxx in enhancement of cyclin D1 expression.
In sum, we have discovered for the first time that the ex-
pression of Daxx mRNA and protein was upregulated in
OSCC clinical samples as well as in OSCC cell lines.
Moreover, knocking down Daxx inhibited cell growth
through inducing G1 cell cycle arrest and decreased cyclin
D1 expression. Hence, Daxx silencing may reduce tumorige-
nicity in OSCC. Thus, it is reasonable to speculate that Daxx
plays an important role in malignant transformation of OSCC
and serves as a potential target for cancer prevention and treat-
ment. Further mechanistic studies may advance our knowl-
edge of the role of Daxx in OSCC and cancer development.
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